Chemotherapy-induced alopecia is universally considered to be one of the most feared side-effects of treatment, with up to 10% of patients either refusing chemotherapy or choosing a less effective regimen to avoid hair loss.1,2
Our systems lead the way in scalp cooling technology, providing easy-to-use, efficacious solutions for clinicians and their patients.
Paxman have over 20 years of experience of implementing scalp cooling systems across the world, and can provide the expertise needed to integrate scalp cooling seamlessly into your clinical practice.
Chemotherapy-induced alopecia can be traumatic, with over 75% of patients citing it was the most feared side effect of their treatment. Chemo hair loss can:3
- Relate to the type and dosage of chemotherapy
- Experience in using scalp cooling
Paxman pride themselves on going above and beyond when supporting patients, providing advice and guidance through every step of the process. From informed decision making at the point of diagnosis, and tutorial videos to ensure the best possible cap fit as well as hair care advice.
We know that an informed patient has a better outcome, which is why education and support is our priority. Visit our patient site coldcap.com for more information.
Oncology centres are innovating their patient-centred care approaches by proactively offering scalp cooling - not just to patients on certain taxane regimens.
Around the world we are seeing the following advanced scalp cooling practices:
Clinicians recognising that patients are being motivated by not only hair retention, but increasingly by faster hair regrowth.
Scalp cooling results in faster recovery of hair volume within 12 weeks after chemotherapy, even in patients for whom scalp cooling fails to prevent CIA 3
A change in attitude on prescribing on anthracyclines. Rather than viewing 40% hair retention as a failure, it is important to recognise that for some patients this could be a preferable alternative to total hair loss.
Patients undergoing anthracycline chemotherapy and receiving scalp cooling were significantly more likely to have less than 50% hair loss after chemotherapy, superior hair regrowth and improvement in patient reported outcomes
Prescribing scalp cooling as standard practice for docetaxel regimens to mitigate the risk of persistent alopecia. For some patients on a docetaxel regimen – particularly those receiving 400mg/m2 dosage or higher - their hair may not grow back after chemotherapy. This is a risk that can be mitigated by using scalp cooling
Patients undergoing anthracycline chemotherapy and receiving scalp cooling were significantly more likely to have less than 50% hair loss after chemotherapy, superior hair regrowth and improvement in patient reported outcomes
28, 12th Cross, Indiranagar 1st Stage
Bangalore 560 038
India
Phone: +91 9844 117 366
Phone: +91 9844 152 284
Fax: +91 80 25282068
E-Mail: accessdevices@gmail.com
1 Kdakia et al. Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage. 2014;47:1100-1115.
2 Roe H. Scalp cooling: management option for chemotherapy-induced alopecia. Br J Nurs. 2014;23(suppl):S4-S12.
3 Kargar et al. Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy. J Advanced Nurs. 2011;67(11):2473-2477. / Roe H. Chemotherapy-induced alopecia: advice and support for hair loss. Br J Nurs. 2011.20 (suppl):S4-S11. / Ross M, Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. CJON. 2017;21(2):226-233. / Kdakia KC et al. Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage. 2014;47:1100-1115. / Roe H. Scalp cooling: management option for chemotherapy-induced alopecia. Br J Nurs. 2014;23(suppl):S4-S12.
